Recombinant Human T-cell surface antigen CD2 (CD2)

What is the molecular structure of CD2 and how does it interact with its ligand LFA3?

CD2 is a glycoprotein with an extracellular domain (ECD) consisting of membrane-distal and membrane-proximal immunoglobulin domains connected by a flexible linker region. The membrane-proximal region is linked to a transmembrane helix, while the membrane-distal domain binds to LFA3 (CD58) .

The CD2-LFA3 interaction occurs primarily through polar interactions including hydrogen bonds and salt bridges between their respective adhesion domains. Structural studies using crystallography have revealed that upon binding, the distance between a T cell and antigen-presenting cell (APC) is approximately 130 Ångström .

The most well-characterized CD2 epitopes include:

• T11.1 region

• T11.2 region

• T11.3 region

• CD2R epitope (exposed upon T cell activation and/or LFA3 binding)

Methodologically, researchers have used X-ray crystallography to determine structures such as:

• CD2 adhesion domain (PDB code: 1HNF; 2.5 Å resolution)

• LFA3 structure (PDB code: 1CCZ; 1.8 Å resolution)

• CD2-LFA3 complex (PDB code: 1QA9; 3.2 Å resolution)

What role does CD2 play in T cell development and thymic selection?

CD2 contributes to multiple stages of thymic development, though its exact functions appear to be context-dependent and influenced by the associated T cell receptor (TCR) . While CD2 is not absolutely required for positive selection of T cells, CD2-deficient mice exhibit subtle defects in thymocyte differentiation .

Key findings regarding CD2's role in thymic development include:

• CD2 influences TCR repertoire selection by affecting Vα gene segment usage in mature T lymphocytes

• CD2-deficiency in T cells bearing TCRs with lower affinity for selecting ligands increases the efficiency of positive selection

• CD2-deficiency in class I-restricted TCR transgenic mice results in differentiation defects during CD25+ to CD25- transition

• Most studies using CD2-deficient mouse models report reduced frequencies of double-positive (DP) thymocytes

• In class II-restricted TCR transgenic mice, CD2 deficiency leads to decreased DP and CD4+ single-positive (SP) thymocytes

For experimental approaches, researchers should consider:

• Using CD2-deficient mouse models with different TCR transgenes

• Employing modern transcriptomics and single-cell TCR sequencing to generate gene expression trajectories and fully map how CD2 affects T cell differentiation and repertoire generation

How does CD2 contribute to immunological synapse formation and T cell activation?

CD2 plays multiple roles in immunological synapse (IS) formation, architecture, and composition. It participates in both early scanning of APCs and subsequent T cell activation events .

In scanning T cells:

• CD2 is enriched in the uropod along with TCR/CD3 and lipid rafts

• This localization suggests CD2 helps in APC scanning prior to IS formation

• CD2 may facilitate formation of the "pre-IS" during probing of APCs

During T cell activation:

• CD2 functions as a positive regulator of TCR signaling intensity

• CD2's contribution is particularly crucial for T cells responding to weaker TCR agonists

• CD2-deficient TCR transgenic T cells show diminished activation, proliferation, and IFN-γ production upon priming

• The magnitude of CD2's effect depends on TCR signal intensity; T cells with high-affinity TCRs are less reliant on CD2 for full immune responses

Experimental evidence shows that:

• Anti-CD2 antibody treatment during priming reduces T cell responses

• A single dose of anti-CD2 monoclonal antibody induces sustained T cell hyporesponsiveness for up to 4 weeks

• Some pathogens, such as certain HCMV strains, have evolved to downregulate LFA3 expression in host cells to evade CTL cytotoxicity, underscoring the pathway's importance

What conformational changes occur in CD2 upon activation, and how can they be experimentally manipulated?

CD2 undergoes significant conformational changes upon T cell activation and/or LFA3 binding, which exposes an epitope called CD2R . This conformational flexibility extends to CD2's ability to fold in multiple ways.

The amino-terminal domain of CD2 has the remarkable property of folding in two distinct conformations:

• As a monomeric form

• As an intertwined, metastable dimer

These alternative folding states can be differentially stabilized through protein engineering approaches:

• By engineering the CD2 sequence, researchers can stabilize either the monomeric or dimeric conformation

• A hinge-deletion mutant has been developed that remains stable as an intertwined dimer

• Crystal structures of this mutant reveal domain rotations that enable further assembly into a tetramer

These findings demonstrate that a single polypeptide sequence can adopt various folds, providing guidance for protein design . Researchers interested in manipulating CD2 conformations should consider:

• Hinge region modifications

• Sequence engineering approaches that mimic evolutionary mutagenesis

• X-ray crystallography to confirm structural arrangements

How does CD2 contribute to T cell migration, and what experimental systems best capture this functionality?

Recent research has uncovered an important role for CD2 in directional T cell migration. CD2 expression on T cells is associated with enhanced migratory capacity, making it a potential phenotypic biomarker for migratory T cells .

Key findings include:

• CD2 transcripts significantly correlate with cellular migration and other migration-associated genes

• Migratory T cells exhibit significantly higher surface expression of CD2 compared to non-migratory cells within the same population

• The interaction between CD2 on T cells and CD58 on target cells (such as lymphoma cells) accelerates T cell migration

Experimental approaches to study CD2-mediated migration include:

• TIMING (Time-lapse Imaging Microscopy In Nanowell Grids) assay to quantify basal migration of T cells in the absence of tumor cells

• Post-migration quantification of CD2 surface abundance by fluorescent immunostaining and microscopy

• Comparison of median fluorescence intensity between migratory and non-migratory cells

• Testing T cells against CD58-negative and CD58-positive target cells to assess the impact of CD2-CD58 interactions

What are the critical differences between murine and human CD2 biology, and how do these impact translational research?

Significant differences exist between CD2 biology in mice and humans, complicating the extrapolation of findings from murine models to human contexts . These differences include:

• Expression patterns:

  • In humans, only a minor percentage of B cells express CD2

  • In mice, CD2 is broadly expressed on B cells

• Binding partners:

  • Humans express LFA3 (CD58) as the primary binding partner for CD2

  • Mice lack LFA3 expression entirely

  • Mice express CD48, which has lower affinity for CD2 and can bind to both CD2 and CD244

• Functional implications:

  • The degree to which murine CD2 data can be extrapolated to humans is uncertain

  • Early studies with CD2 knockout mice or anti-CD2 antibody treatments showed normal immunological phenotypes, undermining the initial view that CD2 plays a major role in T cell development

  • Later studies revealed subtle but important defects in thymocyte differentiation in CD2-deficient mice

For translational researchers, these differences mean:

• Development of suitable animal models for CD2-targeting therapies is resource-intensive

• Only transgenic rodents and primates serve as relevant pre-clinical models

• This explains why most research on CD2 immunobiology has been conducted in vitro

The high degree of conservation of CD2 across rodents and higher mammals does suggest an important evolutionary role, as conservation without selective pressure is unlikely .

What methodologies are most effective for studying CD2-mediated interactions in experimental settings?

Several methodological approaches have proven valuable for studying CD2 biology and function:

• Structural studies:

  • X-ray crystallography to determine CD2, LFA3, and CD2-LFA3 complex structures

  • Structural alignment using software like PyMOL to model binding interactions

  • Protein engineering to create stable CD2 variants with specific conformational properties

• Functional assessments:

  • TIMING assay to quantify T cell migration dynamics

  • Flow cytometry to assess CD2 surface expression levels

  • In vivo studies using anti-CD2 antibodies to evaluate CD2 function during T cell priming

  • CD2-deficient mouse models, particularly with varied TCR transgenes to assess context-dependent effects

• Advanced approaches:

  • Single-cell transcriptomics combined with TCR sequencing to comprehensively map CD2's effects on T cell differentiation and repertoire generation

  • Multidimensional single-cell analysis to identify relationships between CD2 expression and functional parameters like migration

  • Correlation analysis between CD2 transcripts and other functional genes

  • Fluorescent immunostaining and microscopy for post-assay phenotyping of cells based on function

When designing experiments, researchers should consider:

• The potentially different roles of CD2 in developing thymocytes versus mature T cells

• The importance of TCR affinity/avidity in determining CD2's contribution to T cell activation

• Species-specific differences when translating findings between model systems

How does CD2 expression correlate with memory T cell function, and why is this relevant for therapeutic targeting?

CD2 expression is upregulated on memory T cells as well as activated T cells, making it a potentially selective target for therapies aimed at these populations . Its importance in memory T cell function persists despite the presence of other costimulatory pathways .

Therapeutic relevance:

• CD2-targeting biologics have demonstrated safety and efficacy in clinical studies

• Anti-CD2 monoclonal antibodies induce immunomodulatory effects in vitro

• CD2 represents an attractive target for treating pathologies characterized by undesired T cell activation

• CD2-targeting offers a way to more selectively target memory T cells while favoring immune regulation

Functional relationships:

• CD2 may be particularly important for memory T cell responses where rapid activation and specific migration patterns are essential

• The differential expression of CD2 on memory versus naive T cells provides a potential therapeutic window

• Anti-CD2 antibody treatment has been shown to induce sustained T cell hyporesponsiveness for up to 4 weeks, suggesting potential for durable therapeutic effects

What experimental approaches can detect functional differences in CD2-deficient or CD2-blocked T cells?

Researchers have employed various approaches to assess the functional consequences of CD2 deficiency or blockade:

• Mouse models:

  • CD2-deficient mouse strains to study development and activation phenotypes

  • TCR transgenic CD2-deficient models to assess the impact of CD2 in the context of defined TCR specificities

  • Human CD2 transgenic mice to study the role of specific domains like the cytoplasmic tail

• Antibody-based approaches:

  • Anti-CD2 antibody treatment during T cell priming to assess activation outcomes

  • Administration of single-dose anti-CD2 monoclonal antibody to induce sustained hyporesponsiveness

  • Targeting specific CD2 epitopes (T11.1, T11.2, T11.3) to assess domain-specific functions

• Cellular assays:

  • Migration assays to quantify directional movement capabilities

  • Cytokine production (particularly IFN-γ) assessments following stimulation

  • Proliferation assays to measure expansion capacity

  • Cell-cell conjugation and immunological synapse formation analyses

• Combined approaches:

  • Comparing CD2 surface expression with functional outputs at the single-cell level

  • Testing CD2-deficient T cells against target cells with or without CD58 expression

How might recombinant CD2 protein be engineered for enhanced stability or specific functional properties?

The remarkable ability of CD2's amino-terminal domain to fold in two ways (as a monomer or intertwined dimer) provides opportunities for protein engineering . Researchers have demonstrated that:

• The CD2 sequence can be engineered to differentially stabilize either the monomeric or dimeric fold

• A hinge-deletion mutant of CD2:

  • Remains stable as an intertwined dimer

  • Exhibits domain rotations that enable further assembly into a tetramer

  • Demonstrates that a variety of folds can be adopted by a single polypeptide sequence

These findings provide guidance for designing CD2 variants with specific properties:

• Engineering the hinge region could control oligomerization state

• Stabilizing specific conformations might enhance binding to particular partners

• Creating variants that lock CD2 in either its active or inactive conformation could provide valuable research tools

• Domain-specific modifications could potentially separate adhesion functions from signaling capabilities

For researchers developing recombinant CD2 proteins, considering these conformational properties is essential for ensuring consistent activity and stability in experimental and therapeutic applications.